	US 11,780,916 B2
	GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof
Xiaofeng Wang, Zhejiang (CN); Hua Zhang, Zhejiang (CN); Chenjiang Yao, Zhejiang (CN); Cheng Zhang, Zhejiang (CN); and Shuqian Jing, Zhejiang (CN)
Assigned to Gmax Biopharm LLC, Hangzhou (CN)
Appl. No. 16/982,443
Filed by Gmax Biopharm LLC, Zhejiang (CN)
PCT Filed Mar. 19, 2019, PCT No. PCT/CN2019/078671 § 371(c)(1), (2) Date Sep. 18, 2020, PCT Pub. No. WO2019/179424, PCT Pub. Date Sep. 26, 2019.
Claims priority of application No. 201810231468.X (CN), filed on Mar. 20, 2018.
Prior Publication US 2021/0061904 A1, Mar. 4, 2021
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 9/00 (2006.01)

CPC C07K 16/28 (2013.01) [A61K 9/0019 (2013.01); C07K 2317/565 (2013.01)]

27 Claims

1. An antibody that specifically binds to human gastric inhibitory polypeptide receptor (GIPR), wherein the antibody comprises:

a. a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13;

b. a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11;

c. a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 14;

d. a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 26;

e. a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27; and

f. a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 28.